Cargando…

Acute pulmonary emboli following rebound phenomenon after Nirmatrelvir/Ritonavir treatment for COVID-19

Detalles Bibliográficos
Autores principales:	Zheng, Qian, Ma, Pengfei, Feng, Zhanhui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Inc. 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9771576/ https://www.ncbi.nlm.nih.gov/pubmed/36577594 http://dx.doi.org/10.1016/j.ajem.2022.12.027

Ejemplares similares

Acute pulmonary emboli following rebound phenomenon after Nirmatrelvir/Ritonavir treatment for COVID-19
por: Birabaharan, Morgan, et al.
Publicado: (2022)

Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir
por: Wong, Grace Lai-Hung, et al.
Publicado: (2022)

Nirmatrelvir–Ritonavir and Viral Load Rebound in Covid-19
por: Anderson, Annaliesa S., et al.
Publicado: (2022)

Rebound of SARS-CoV-2 Infection after Nirmatrelvir–Ritonavir Treatment
por: Charness, Michael E., et al.
Publicado: (2022)

Virological and clinical rebounds of COVID-19 soon after nirmatrelvir/ritonavir discontinuation
por: Antonelli, Guido, et al.
Publicado: (2022)

COVID-19 “Rebound” associated with nirmatrelvir/ritonavir pre-hospital therapy
por: Coulson, J.M., et al.
Publicado: (2022)

SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy
por: Edelstein, Gregory E., et al.
Publicado: (2023)

COVID-19 redux: clinical, virologic, and immunologic evaluation of clinical rebound after nirmatrelvir/ritonavir
por: Epling, Brian P., et al.
Publicado: (2022)

Clinical characteristics of COVID-19 rebound after nirmatrelvir-ritonavir or molnupiravir therapy: A prospective cohort study
por: Han, Jaijun, et al.
Publicado: (2023)

Nirmatrelvir-ritonavir for COVID-19
por: McDonald, Emily G, et al.
Publicado: (2022)

Nirmatrelvir and ritonavir for COVID-19
Publicado: (2022)

Does Nirmatrelvir/Ritonavir Influence the Immune Response against SARS-CoV-2, Independently from Rebound?
por: Panza, Francesca, et al.
Publicado: (2023)

Immunologic characterization of a patient with clinical and virologic rebound upon Nirmatrelvir/Ritonavir treatment: the unfortunate epilogue of COVID-19
por: Marchetti, Giulia, et al.
Publicado: (2023)

Nirmatrelvir Plus Ritonavir: First Approval
por: Lamb, Yvette N.
Publicado: (2022)

Nirmatrelvir/ritonavir as a possible treatment for Long-COVID
por: Catalán, Ignacio Pérez, et al.
Publicado: (2023)

Possible medication error risks with nirmatrelvir+ritonavir
Publicado: (2022)

Correction to: Nirmatrelvir Plus Ritonavir: First Approval
por: Lamb, Yvette N.
Publicado: (2022)

Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
por: Lu, Jiayue, et al.
Publicado: (2023)

Virologic and Immunologic Characterization of COVID-19 Recrudescence after Nirmatrelvir/Ritonavir Treatment
por: Carlin, Aaron F., et al.
Publicado: (2022)

Association nirmatrelvir/ritonavir contre la COVID-19
por: McDonald, Emily G., et al.
Publicado: (2022)

Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19
por: Reis, Stefanie, et al.
Publicado: (2022)

Benefits of nirmatrelvir–ritonavir remain unproven for some populations
por: McDonald, Emily G., et al.
Publicado: (2022)

Nirmatrelvir/ritonavir (Paxlovid®): French pharmacovigilance survey 2022
por: Bihan, Kevin, et al.
Publicado: (2023)

Real-world use of nirmatrelvir–ritonavir: who benefits?
por: Molina, Kyle C, et al.
Publicado: (2023)

Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19
por: Reis, Stefanie, et al.
Publicado: (2023)

483. Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with Hemodialysis
por: Li, Xin, et al.
Publicado: (2023)

VV116 versus Nirmatrelvir–Ritonavir for Oral Treatment of Covid-19
por: Cao, Zhujun, et al.
Publicado: (2022)

Post-acute hospitalization and mortality of nirmatrelvir plus ritonavir for COVID-19 survivors
por: Hsu, Wan-Hsuan, et al.
Publicado: (2023)

Can nirmatrelvir/ritonavir treatment shorten the duration of COVID-19 isolation?
por: Kim, Haein, et al.
Publicado: (2022)

Osteoclast Recycling and the Rebound Phenomenon Following Denosumab Discontinuation
por: Kim, Albert S., et al.
Publicado: (2022)

Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?
por: Hung, Yuan-Pin, et al.
Publicado: (2022)

Generalized use of Nirmatrelvir plus ritonavir (Paxlovid): Raising concerns
por: Sánchez Fabra, David, et al.
Publicado: (2023)

Generalized use of Nirmatrelvir plus ritonavir (Paxlovid): Raising concerns
por: Sánchez Fabra, David, et al.
Publicado: (2023)

Inpatient remdesivir versus nirmatrelvir-ritonavir in the progression of COVID-19
por: Patel, Dimple, et al.
Publicado: (2023)

523. Efficacy and Safety of Nirmatrelvir/Ritonavir for COVID-19 in Adolescents
por: Lee, Kiriam Escobar, et al.
Publicado: (2023)

Treatment of acute tacrolimus toxicity with phenytoin after Paxlovid (nirmatrelvir/ritonavir) administration in a kidney transplant recipient
por: Kwon, Eun-Jeong, et al.
Publicado: (2022)

930. COVID-19 symptom and viral load rebound among individuals reporting nirmatrelvir/ritonavir use compared to propensity score matched individuals not taking COVID-19 treatment
por: Smith-Jeffcoat, Sarah E, et al.
Publicado: (2023)

511. Risk Factors for Seeking Medical Care Following Nirmatrelvir-Ritonavir (Paxlovid) Treatment For COVID-19
por: Bhargava, Ashish, et al.
Publicado: (2023)

New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19
por: Atmar, Robert L., et al.
Publicado: (2022)

Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir
por: Akinosoglou, Karolina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bp7tl79ujj95lokduj9vvhvvsp